Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | DTYMK | P23919 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775824 | 0.84 | POLB (0.47) | GPR119POLBPDE10AGRM5DTYMK | |
| SCHEMBL5748387 | 0.80 | POLB (0.41) | USP30GPR119POLBPDE10AGRM5 | |
| SCHEMBL5747116 | 0.80 | POLB (0.41) | GPR119POLBPDE10AKDM4EGRM5 | |
| SCHEMBL5636825 | 0.80 | JAK1 (0.40) | PDE10A | |
| SCHEMBL5748603 | 0.80 | POLB (0.41) | GPR119POLBPDE10AKDM4EGRM5 | |
| SCHEMBL5509551 | 0.78 | ALDH1A1 (0.42) | GPR119POLBALOX5APFEN1 | |
| SCHEMBL5801156 | 0.77 | POLB (0.39) | GPR119POLBGRM5DTYMK | |
| SCHEMBL5636179 | 0.76 | KDM4D (0.33) | PDE10AKDM4E | |
| SCHEMBL3577407 | 0.76 | KDM4D (0.32) | PDE10AKDM4E | |
| SCHEMBL5530322 | 0.75 | ACACB (0.40) | KDM4EADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
| EP-2245028-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009077989-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | USP30 3264/4885GPR119 2186/4885POLB 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.